Arsenic Induces Functional Re-Expression of Estrogen Receptor α by Demethylation of DNA in Estrogen Receptor-Negative Human Breast Cancer
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Estrogen receptor α (ERα) is a marker predictive for response of breast cancers to endocrine therapy. About 30% of breast cancers, however, are hormone- independent because of lack of ERα expression. New strategies are needed for re-expression of ERα and sensitization of ER-negative breast cancer cells to selective ER modulators. The present report shows that arsenic trioxide induces reactivated ERα, providing a target for therapy with ER antagonists. Exposure of ER-negative breast cancer cells to arsenic trioxide leads to re-expression of ERα mRNA and functional ERα protein in in vitro and in vivo. Luciferase reporter gene assays and 3-(4,5-dimethylthiazol-2-yl)- 5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assays show that, upon exposure to arsenic trioxide, formerly unresponsive, ER-negative MDA-MB-231 breast cancer cells become responsive to ER antagonists, 4-hydroxytamoxifen and ICI 182,780. Furthermore, methylation- specific PCR and bisulfite-sequencing PCR assays show that arsenic trioxide induces partial demethylation of the ERα promoter. A methyl donor, S-adenosylmethionine (SAM), reduces the degree of arsenic trioxide-induced re-expression of ERα and demethylation. Moreover, Western blot and ChIP assays show that arsenic trioxide represses expression of DNMT1 and DNMT3a along with partial dissociation of DNMT1 from the ERα promoter. Thus, arsenic trioxide exhibits a previously undefined function which induces re-expression ERα in ER-negative breast cancer cells through demethylation of the ERα promoter. These findings could provide important information regarding the application of therapeutic agents targeting epigenetic changes in breast cancers and potential implication of arsenic trioxide as a new drug for the treatment of ER-negative human breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Arsenic is a Group 1 carcinogen that can increase the risk of breast cancer (54) and has been shown to induce expression of the estrogen receptor in human breast cancer (55).”
From The human tumor microbiome is composed of tumor type–specific intracellular bacteria (2020) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777 · cited 1×
“result of hypermethylation of CpG islands, cytosine–guanine-rich areas that are located in the 59 regulatory regions of the ER gene [2,7,8].”
BackgroundEstrogen receptor interaction with estrogen response elements
Klinge, C. M. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.14.2905 · Cited by 1,081
Chen, G., Shi, X., Tang, W., Xiong, S. M., Zhu, J., Cai, X., Han, Z., Ni, J.-H., Shi, G., Jia, P.-M., et al. (1997) · PubMed · Cited by 862
Mechanisms of arsenic biotransformation
Vahter, M. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00285-8 · Cited by 757 · cited 1×
“SAM as a methyl donor [34,35], the consumption of methyl groups in arsenic biotransformation presumably results in a”
BackgroundBreast cancer: origins and evolution
Polyak, K. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33295 · Cited by 697 · cited 1×
“disease that is driven by epigenetic alterations, which do not affect the primary DNA sequence [5,6].”
Background(1990) · PubMed · Cited by 612
Ottaviano, Y. L., Issa, J. J., Parl, F. F., Smith, H. S., Baylin, S. B., & Davidson, N. E. (1994) · PubMed · Cited by 559
Yang, X., Phillips, D. L., Ferguson, A. T., Nelson, W. G., Herman, J. G., & Davidson, N. E. (2001) · PubMed · Cited by 500
DNA methylation controls the inducibility of the mouse metallothionein-I gene in lymphoid cells
Compere, S. J., & Palmiter, R. D. (1981) · Cell · doi:10.1016/0092-8674(81)90248-8 · Cited by 465 · cited 1×
“Arsenic methylation requires SAM as a cofactor and, as yet, largely uncharacterized methyltransferases (MeTases), including DNA MeTases (DNMTs), a group of enzymes responsible for DNA methylation. Expression of the DNMT gene has been definitively linked to methylation status”
BackgroundDNA methylation and breast carcinogenesis
Widschwendter, M., & Jones, P. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205606 · Cited by 457 · cited 1×
“disease that is driven by epigenetic alterations, which do not affect the primary DNA sequence [5,6].”
BackgroundRae, J. M., Creighton, C. J., Meck, J. M., Haddad, B. R., & Johnson, M. D. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9392-8 · Cited by 374 · cited 1×
“. However, there is evidence that MDA-MB-435 cell line is not actually from a breast cancer lineage, but in fact are derived from a melanoma cell line, M14”
BackgroundPlatet, N., Cathiard, A. M., Gleizes, M., & Garcia, M. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.02.001 · Cited by 367
Hormone receptors: their role in predicting prognosis and response to endocrine therapy.
McGuire, W. L. (1978) · PubMed · Cited by 335
Mass, M. J., & Wang, L. (1997) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(97)00008-2 · Cited by 309 · cited 2×
“deficiency of methyl donors, reducing DNA methylation [10].”
BackgroundYang, X., Ferguson, A. T., Nass, S. J., Phillips, D. L., Butash, K. A., Wang, S. M., Herman, J. G., & Davidson, N. E. (2000) · PubMed · Cited by 268
Roodi, N., Bailey, L. R., Kao, W.-Y., Verrier, C. S., Yee, C. J., Dupont, W. D., & Parl, F. F. (1995) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/87.6.446 · Cited by 266
Cai, X., Shen, Y.-L., Zhu, Q., Jia, P.-M., Yu, Y., Zhou, L., Huang, Y., Zhang, J.-W., Xiong, S.-M., Chen, S.-J., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401650 · Cited by 260 · cited 1×
“This compound induces apoptosis and has growth-suppressive effects as a treatment for acute promyelocytic leukemia and solid tumors [27,28,29,30].”
BackgroundSharma, D., Saxena, N. K., Davidson, N. E., & Vertino, P. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0402 · Cited by 208 · cited 1×
“Arsenic trioxide induced restoration of ERa function in ER-negative human breast cancer cells Estrogen exerts its effects by binding to ER, which functions as transcription factor controlling cell proliferation and differentiation [14,15].”
BackgroundMapping of ER gene CpG island methylation-specific polymerase chain reaction.
Lapidus, R. G., Nass, S. J., Butash, K. A., Parl, F. F., Weitzman, S. A., Graff, J. R., Herman, J. G., & Davidson, N. E. (1998) · PubMed · Cited by 206
The Loss of Estrogen and Progesterone Receptor Gene Expression in Human Breast Cancer
Lapidus, R. G., Nass, S. J., & Davidson, N. E. (1998) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1018778403001 · Cited by 192 · cited 1×
“and are not generally associated with loss of ER [4].”
BackgroundHu, Y., Su, L., & Snow, E. T. (1998) · Mutation Research/DNA Repair · doi:10.1016/s0921-8777(98)00035-4 · Cited by 184 · cited 1×
“Arsenic trioxide, an inhibitor of sulfhydryl enzymes, inhibits the activity of DNMT3a and DNMT3b, both of which contain cysteine sulfhydryl groups [38,39].”
BackgroundEpigenetic Information and Estrogen Receptor Alpha Expression in Breast Cancer
Giacinti, L., Claudio, P. P., Lopez, M., & Giordano, A. (2006) · The Oncologist · doi:10.1634/theoncologist.11-1-1 · Cited by 183 · cited 1×
“and is predictive of response to endocrine therapy [1].”
BackgroundCui, X., Wakai, T., Shirai, Y., Yokoyama, N., Hatakeyama, K., & Hirano, S. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.10.013 · Cited by 144
Effects of Arsenite on Estrogen Receptor-α Expression and Activity in MCF-7 Breast Cancer Cells1
Stoica, A., Pentecost, E., & Martin, M. B. (2000) · Endocrinology · doi:10.1210/endo.141.10.7704 · Cited by 144 · cited 1×
“Arsenic trioxide, as an endocrine-disrupting chemical, act as hormone mimetic and as either agonist or competitive antagonist dependent on the level of endogenous estrogens. It is now generally accepted that ER protein is targeted for rapid degradation via the ubiquitin- proteasome pathway in response to E2 in breast…”
BackgroundThe Role of Estrogen in Mammary Carcinogenesisa
FISHMAN, J., OSBORNE, M. P., & TELANG, N. T. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb12113.x · Cited by 140 · cited 1×
“ERα, a predictor of prognosis and response to endocrine therapy, functions in development of normal breast tissue. It has also been linked to mammary carcinogenesis, breast tumor progression, and outcomes for breast cancer patients”
BackgroundArsenic trioxide: Mechanisms of action
Davison, K. L., Mann, K. K., & Miller, W. H. (2002) · Seminars in Hematology · doi:10.1053/shem.2002.33610 · Cited by 103 · cited 2×
“Arsenic trioxide, which has been used clinically as an anti-tumor agent, induces demethylation and apoptosis [9], while little is known regarding the mechanism of its anti-tumor effect.”
BackgroundTowards a molecular basis for tamoxifen resistance in breast cancer
Johnston, S. R. D., Dowsctt, M., & Smith, I. E. (1992) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058251 · Cited by 56
Chow, S. K., Chan, J. Y., & Fung, K. (2004) · Journal of Endocrinology · doi:10.1677/joe.0.1820325 · Cited by 49 · cited 2×
“[25], inhibiting it in the presence of hormone (RPMI 1640”
BackgroundTakeyoshi, M., Yamasaki, K., Sawaki, M., Nakai, M., Noda, S., & Takatsuki, M. (2002) · Toxicology Letters · doi:10.1016/s0378-4274(01)00446-5 · Cited by 47 · cited 1×
“The plasmids were constructed as previously described [11].”
MethodLiu, H., Du, J., Hu, C., Qi, H., Wang, X., Wang, S., Liu, Q., & Li, Z. (2009) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.01.016 · Cited by 41
Self-citationBechthold, A., & Floss, H. G. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.00431.x · Cited by 40
Li, Q., Bartlett, D. L., Gorry, M. C., O’Malley, M. E., & Guo, Z. S. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.056291 · Cited by 40 · cited 1×
“[42,43], we found that arsenic trioxide also inhibits DNMT3a protein in ER-negative breast cancer cells.”
BackgroundAntitumor effect of arsenic trioxide in murine xenograft model
Kito, M., Matsumoto, K., Wada, N. A., Sera, K., FUTATSUGAWA, S., Naoe, T., Nozawa, Y., & Akao, Y. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01393.x · Cited by 39 · cited 1×
“This compound induces apoptosis and has growth-suppressive effects as a treatment for acute promyelocytic leukemia and solid tumors [27,28,29,30].”
BackgroundZhang, P., Wang, S., Hu, L., Qiu, F., Yang, H., Xiao, Y., Li, X., Han, X., Zhou, J. L., & Liu, P. (2000) · PubMed · Cited by 32
Waalkes, M. P., Miller, M. S., Wilson, M. J., Bare, R. M., & Mcdowell, A. E. (1988) · Chemico-Biological Interactions · doi:10.1016/0009-2797(88)90071-3 · Cited by 28
Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis
González-Fraile, M. I., García‐Sánz, R., Mateos, M., Balanzategui, A., González, M., Váquez, L., & Miguel, J. F. S. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03502.x · Cited by 24 · cited 1×
“SAM as a methyl donor [34,35], the consumption of methyl groups in arsenic biotransformation presumably results in a”
BackgroundThe silent estrogen receptor--can we make it speak?
Billam, M., Witt, A. E., & Davidson, N. E. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.6.7582 · Cited by 21 · cited 1×
“Although mechanisms for the lack of ERa expression in breast cancer have been investigated [20]; hypermethylation of the ERa promoter represents the first identified mechanism.”
BackgroundCrooks, P. A., Tribe, M. J., & Pinney, R. J. (1984) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1984.tb02999.x · Cited by 19
Lu, S. (2011) · Oncology Reports · doi:10.3892/or.2011.1352 · Cited by 17
[Arsenic trioxide induced p15INK4B gene expression in myelodysplastic syndrome cell line MUTZ-1].
Tong, H., & Lin, M. (2002) · PubMed · Cited by 7
[Re-expression of p16 gene in myeloma cell line U266 by arsenic trioxide].
Li, J., Li, Y., Shi, Y.-J., & Wu, S. (2004) · PubMed · Cited by 4
[Effect of As2O3 on demethylation of SHP-1 gene in human lymphoma cell line T2].
Yang, L., Luo, J., Wen, S.-P., Liu, X., Du, X.-Y., & Li, Y. (2009) · PubMed · Cited by 3
Wang, M., Dou, H.-J., Zou, L.-F., Zhu, Q., Ren, Z., & Hu, J.-P. (2008) · PubMed · Cited by 2
Cited by
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science · doi:10.1126/science.aay9189 · Cited by 2,464
DNMT1: A key drug target in triple-negative breast cancer
Wong, K. K. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.010 · Cited by 198
Koestler, D. C., Avissar-Whiting, M., Houseman, E. A., Karagas, M. R., & Marsit, C. J. (2013) · Environmental Health Perspectives · doi:10.1289/ehp.1205925 · Cited by 178
“…ESR1 is consistent with a report of decreased methylation and increased expression of ESR1 with in vitro arsenic exposure in a breast cancer model (Du et al. 2012), whereas the association with PPARGC1A is consistent with a report demonstrating up-regulation of this gene in arsenicinduced Bowen’s…”
ResultPremature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women
Honigberg, M. C., Zekavat, S. M., Niroula, A., Griffin, G. K., Bick, A. G., Pirruccello, J. P., Nakao, T., Whitsel, E. A., Farland, L. V., Laurie, C., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051775 · Cited by 147
Genotoxic and epigenetic mechanisms in arsenic carcinogenicity
Bustaffa, E., Stoccoro, A., Bianchi, F., & Migliore, L. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1233-7 · Cited by 159
“At the same time, gene-specific hypomethylation of several genes, such as p16, RASSF1, E-cadherin, and GSTP1, was found (Cui et al. 2006a; Du et al. 2012).”
Background
Metadata
- Authors
- Du, J., Zhou, N., Liu, H., Jiang, F., Wang, Y., Hu, C., Qi, H., Zhong, C., Wang, X., & Li, Z.
- Affiliations
- Nanjing Medical University (CN)
- State Key Laboratory of Reproductive Medicine (CN)
- Corresponding author
- Li, Zhong
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-04-27
- Volume
- 7
- Issue
- 4
- Pages
- e35957
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3338760
- OpenAlex
- W2014235860
- Cited by
- 65
- References
- 43
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 1 · 2023: 3 · 2022: 4 · 2021: 5 · 2020: 6 · 2019: 5 · 2018: 3 · 2017: 4 · 2016: 10 · 2015: 2 · 2014: 10 · 2013: 6 · 2012: 1
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (30901186, 30972507, 863 Program)
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Qinglan Project of Jiangsu Province of China
- National High-tech Research and Development Program
- National Institute on Alcohol Abuse and Alcoholism (R21AA023001)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- arsenic trioxide, estrogen receptor alpha, estrogen receptor-negative breast cancer, promoter demethylation, DNA methylation, epigenetic reprogramming, DNMT1, DNMT3A, 4-hydroxytamoxifen, fulvestrant, S-adenosylmethionine, MDA-MB-231 cells, selective estrogen receptor modulators, endocrine therapy sensitivity
- MeSH terms
- DNA (Cytosine-5-)-Methyltransferase 1, Arsenic Trioxide, Animals, Arsenicals, Breast Neoplasms, DNA (Cytosine-5-)-Methyltransferases, DNA-Binding Proteins, Drug Screening Assays, Antitumor, Female, Humans, Mice, Nude, Neoplasm Proteins, Oxides, Promoter Regions, Genetic, Protein Binding, RNA, Messenger, Gene Expression Regulation, Neoplastic, Polymerase Chain Reaction, Sequence Analysis, DNA, CpG Islands, DNA Methylation, Cell Line, Tumor, Estrogen Receptor alpha, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.